Lara McGrath

5PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 31, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.

Tina Cascone, Laura Bonanno, Florian Guisier

|Oct 11, 2023
Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma.

Maria Secrier, Lara McGrath, Felicia Ng

|Sep 14, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.

Tina Cascone, Gozde Kar, Jonathan D Spicer

|Feb 13, 2023
Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T-Cell Activation in Tumors.

Ben Umiker, Yasmin Hashambhoy-Ramsay, Jeff Smith

|May 05, 2022
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.

Timothy A Yap, Justin F Gainor, Margaret K Callahan

Pageof 1

Frequent Collaborators

2 joint publications

Rosario García-Campelo

2 joint publications

Patrick M Forde

2 joint publications

Italia Grenga

2 joint publications

Jonathan Spicer